Experts in health economics,
pricing and reimbursement
PHMR is an international team of highly qualified health economists and research scientists

The carefully curated multidisciplinary team at PHMR is comprised of highly qualified health economists and research scientists. This international collective of dedicated professionals provides in depth understanding of global markets and the capacity to work seamlessly in local languages.


Their combined insight from extensive industry specific experience in global pharmaceutical companies, academic positions and health economics consultancies ensures that PHMR’s clients always receive reliable, expert advice.

Mark Ratcliffe
Mark Ratcliffe
Mark is the founder of PHMR and has developed the company into a successful health economics, pricing and market access consultancy working with a range of top 10 pharma companies. He has a vast amount of experience in the health economics, pricing, reimbursement and market access fields. He also possesses decades of experience with major international pharmaceutical companies and previous work in senior economics research positions.
Louise Longworth
Louise Longworth
Louise has extensive experience in health economics and health technology assessment and a deep understanding of the methods of health technology assessment. As chief scientific officer at PHMR, Louise advises on the development of HTA strategy and evidence submissions in a wide range of therapeutic areas. Louise has specialist expertise in patient-reported outcomes and utility measurement. She has been a member of the EuroQol Group, the organisation responsible for the development of the EQ-5D instruments, for most of her career and currently holds a position on the Board of Directors. She has held various roles with NICE, including as Technical Adviser in the Technology Appraisals programme, leader of independent evidence reviews, member of its Decision Support Unit, and member of its Technology Appraisal Committee. Louise has published extensively on health economics methodology and HTA policy.
Michael Lees
Michael is involved across a range of health economics, outcomes research and market access projects at PHMR. As chief operating officer at PHMR, he is responsible for ensuring that the research delivered matches the strategic needs of our clients. Michael has extensive experience in the development of health economic models and indirect treatment comparisons, utility measurement and health valuation, strategies for collection and use of real-world data, and the development of dossiers to support HTA submission. He also has substantial experience in working with different stakeholders, including through the use of early scientific advice through HTA agencies, to lead the development of integrated evidence plans and allow for access needs to be incorporated from early in product development. Michael has led projects across many different therapeutic areas, with expertise in fields including oncology, gastroenterology, neuroscience, rare disease, and cardiovascular disease. Michael has also published his research in peer-reviewed journals and presented work at multiple international conferences. He has led educational initiatives to shape HTA policy, which involved delivering symposiums at international conferences and developing publications to support the use of innovative methodologies to demonstrate the value of new immuno-oncology medicines.
Cormac Sammon
Cormac Sammon
Cormac is an epidemiologist and has successfully delivered clinical and economic research projects for a variety of clients, utilising real-world data to contribute across the drug development process, from establishing the clinical and economic burden of disease to informing key parameters of cost-effectiveness models and monitoring the long-term post-marketing safety and effectiveness of drugs. Cormac’s expertise in generating and interpreting complex clinical and economic data and utilising it to demonstrate the value of emerging technologies has led him to successfully lead a broadening portfolio of health economics and outcomes research projects, including systematic and pragmatic literature reviews, economic models, and HTA submissions for NICE, SMC, and NCPE. He has been published extensively across a range of clinical, therapeutic, and methodologic areas.
Koonal Shah
Koonal is a health economist with expertise in stated preference methods, the measurement and valuation of health, and the use of social value judgements in HTA decision making. He has written extensively on patient-reported outcomes and HTA policy (focusing on the assessment of cancer and end of life treatments) and has published over 40 peer-reviewed journal articles and book chapters. He has led high-profile projects across a broad range of clinical and methodological areas, with his work on the generation and analysis of utility values used in a large number of HTA submissions. Koonal is a member of the EuroQol Group (an international network of researchers that developed the EQ-5D family of instruments) and currently serves on the Group’s Executive Committee. He is also an Honorary Research Fellow at the University of Sheffield’s School of Health and Related Research.
Donna Fountain
Donna Fountain
Donna has extensive experience in leading and delivering a wide range of projects to support pharmaceutical companies with their health economics and outcomes research needs as well as maximising market access/reimbursement for new pharmaceutical and diagnostic interventions. As head of market access science at PHMR, she specialises in conducting systematic and targeted literature reviews to support HTA submissions and market access strategy, as well as global value dossier development, stakeholder engagement, reimbursement and landscape mapping, and peer-review manuscript development. Donna has extensive knowledge of multiple therapeutic areas, including oncology, chronic kidney disease, gastrointestinal disorders, cardiovascular disease, age-related disease, and orphan diseases. Donna has also published her research in peer-reviewed journals and presented work at multiple international conferences. Donna holds a PhD in virology and immunology from the University of Nottingham.
Matt Glover
Matt is a health economist with extensive experience in conducting economic evaluations of new treatments and specialises in long-term modelling, with knowledge of a variety of software and conceptual models. He has contributed to and advised biopharma clients on submissions to a number of HTA agencies. He has also contributed health economic input to the design of numerous randomised controlled trials and analysed and synthesised trial data.
Waqas Ahmed
Waqas is a health economist with a background in clinical pharmacy. Since joining PHMR, he has been involved in projects examining the content validity of a range of preference-based measures of health outcomes, as well as preference elicitation studies involving the person trade-off and discrete choice experiment methodologies. Waqas holds an MSc in health economics from the University of York.
Frauke Becker
Frauke is an experienced health economics and outcomes researcher with a strong background in advanced econometric methods. She has a wealth of knowledge in health technology assessment and preference elicitation in a range of settings. Frauke has conducted research in academia in both the United Kingdom and Germany for more than 15 years, having contributed to the development and health economic design of numerous randomised controlled trials. She has been a member of several guideline development groups, providing health economic input to clinical guidelines for NICE in the United Kingdom.
Vlad Berdunov
Vlad is a health economist with substantial experience of leading cost-effectiveness and budget impact modelling projects. He has extensive knowledge of statistical methods applicable to economic evaluation through his experience in trial-based economic evaluation and decision-analytic modelling to support HTA submissions. Vlad has expertise in long-term modelling in rare diseases, including therapeutic areas with sparse evidence of long-term costs and benefits of treatment. His other research interests include the application of propensity scores to adjust for confounding in observational studies and the use of indirect comparisons of efficacy of treatments in the absence of head-to-head trials.
Megan Besford
Megan Besford
Megan has conducted a wide range of statistical analyses, such as indirect treatment comparisons and real-world evidence synthesis, including network meta-analyses, matching-adjusted indirect comparisons, and large patient-level health record analyses. She is experienced in many common and novel statistical methods used in the pharmaceutical industry and utilises both frequentist and Bayesian frameworks. She is also proficient with multiple programming languages, including SAS, R, and WinBUGS. Megan has published research in peer-reviewed journals and presented work at international conferences in several therapeutic areas, including oncology, rare diseases, and cardiology. Megan is a member of the Royal Statistical Society and is working towards Chartered Statistician status.
Lynsey Boyce
Lynsey is the scientific office manager and administrator at PHMR. Her extensive experience in the life sciences and with rapidly growing healthcare consultancies results in a skill set that bridges the gap between business and science. She is passionate about bringing PHMR’s values to life by facilitating and supporting the development of lasting client partnerships; the delivery of quality science with integrity; and the cultivation of a supportive, skill-sharing environment. Her drive to optimise organisation and efficiency reinforces the delivery of PHMR’s consistently high standards.
Rebecca Brown
Rebecca is a market access researcher with expertise in project management of HTA reviews and systematic, targeted, and pragmatic reviews. Rebecca has extensive experience in performing reviews of clinical, economic, utilities, and real-world evidence with the aim of supporting HTA submissions. Rebecca has also performed HTA reviews and analysed pricing and reimbursement data to provide strategic recommendations. Rebecca has contributed to the writing of multiple manuscripts, abstracts, poster presentations, and slide decks for a variety of audiences. She has experience in multiple disease areas including nutrition, ageing, gastrointestinal disease, musculoskeletal disease, and rare diseases. Rebecca holds a PhD in ageing and health from Newcastle University.
Gintare Cepinskaite
Gintare Cepinskaite
Gintare, Assoc CIPD, keeps HR operations aligned to the company values and brings the skills, knowledge, and energy required to ensure PHMR is a great place to work.
Henrique Duarte
An experienced health economist, Henrique develops market access and pricing strategies for clients while also contributing to health economics and HTA projects. Henrique has worked in market access, health economics, and pricing within consultancy and the pharmaceutical industry in the United Kingdom, Portugal, and France, leading market access projects in Europe and key markets outside Europe. He has particular experience with the development of global value dossiers and value messages to drive these dossiers, as well as in the development of strategic evidence plans and economic tools to communicate value. In addition, Henrique’s experience of working at Infarmed (the Portuguese HTA authority) gives him an acute understanding of HTA and payer needs that inform all of his work. Henrique has a PharmD in pharmaceutical sciences from the Universidade Lusófona de Humanidades e Tecnologias and an MSc in health economics from the University of York.
Jasmine Farrington
Jasmine develops and supports HTA and market access strategy and has experience collaborating with national affiliates on behalf of our global clients. Jasmine provides project management and delivery for multiple aspects of HTA evidence generation, including systematic literature reviews, landscape analyses, HTA reviews, pricing research, and engagements with key opinion leaders. Jasmine also contributes to PHMR’s operations and enjoys optimising organisation and communication for our projects to progress rapidly, efficiently, and to the highest standards. Jasmine has considerable experience in the analysis of HTA policy, including novel reimbursement frameworks for cell and gene therapies. Jasmine has worked in the United Kingdom and Europe for world-leading pharmaceutical companies. She has published in several peer-reviewed journals and has presented her research at a number of international conferences.
India Flint
India Flint
India has managed a range of health economic and outcomes research projects at PHMR. Her expertise enables her to conduct both quantitative and qualitative research, including mapping methods for estimation of health state utility, analysis of patient-reported outcomes, patient preference studies, and the development and execution of feasibility assessments. She has also supported the building and reviewing of economic models such as cost-effectiveness and budget impact models. India has worked across a variety of disease areas, including rare diseases and epilepsy. India holds an MSc in health economics from the University of York.
Lefteris Floros
Lefteris Floros
Lefteris has a broad knowledge of health economics having served in multiple academic and commercial positions. He holds extensive experience with the collection, evaluation, and modelling of clinical and cost data having led the development of multiple global and regional economic models for HTA submission purposes, and having designed numerous clinical trial-based economic evaluations. He also carries great familiarity with HTA agency processes having been a part of the technical teams supporting expert committees of UK NICE clinical guidelines and represented pharmaceutical clients in agency committee discussions. His experience also expands in the generation of comprehensive economic value stories for pharmaceutical products used in discussions with payers.
Daniella Foster
Daniella is a market access researcher who develops global value dossiers and conducts systematic and targeted literature reviews that generate evidence for HTA submissions. Daniella has experience in several disease areas, including neurology, renal disease, and oncology. Daniella’s interest in market access across Europe has informed a variety of HTA projects and development of training materials, as well as the PHMR monthly Market Access Alert service, which aims to keep clients informed on HTA decisions and key updates in the United Kingdom, Germany, and France.
Dave Fox
Dave Fox
Dave has considerable experience in the information and library field supporting health research. He is responsible for designing literature searches and strategies, as well as managing the results of searches using reference management software to facilitate the wide variety of projects and research that PHMR undertakes for clients. He has run literature searches for numerous reviews, including NICE single and multiple technology assessments, Cochrane reviews, Public Health Research Council projects, and British Thoracic Society clinical guidelines.
Louise Francis
Louise has considerable experience in all stages of systematic and targeted literature reviews to inform HTA decisions and has worked on a broad range of projects in multiple disease areas, including oncology, neurology, and renal disease. Louise has a keen interest in value communications and contributes to the development of global value dossiers to help our clients demonstrate the value of their products. Louise is also involved in PHMR’s monthly Market Access Alert service, which allows clients to keep up to date with HTA decisions. Louise holds a PhD in nutrition.
Adam Gibson
Adam is a health economics and outcomes researcher with a wealth of knowledge in conducting both quantitative and qualitative research in health valuation, utility measurement, patient and caregiver-reported outcomes, and psychometric testing. He has supported projects across a range of indications, such as oncology, musculoskeletal and rare disease, and psychological and mood disorders. Adam has contributed to the generation of evidence for outcomes dossiers and economic models, and he has advised on outcomes data collection for clinical trials. He has also published and presented research on patients’ treatment experiences at international conferences and in peer-reviewed journals.
Nicola Illingworth
Nicola Illingworth
Nicola has conducted focussed and pragmatic literature reviews and contributed to projects on clinical trial design and burden of illness studies, global HTA strategies and the use of patient reported outcome measures in HTA. Nicola has extensive experience in clinical trial method development and has developed skills in data extraction and data management, presenting reports in the form of slide decks or word documents, as well the preparation of manuscripts and posters.
Persefoni Ioannou
Persefoni Ioannou
As a market access researcher, Persefoni manages and delivers a wide range of projects in support of market access and reimbursement activities for pharmaceuticals and medical devices. She has extensive experience in value communications, focusing on building effective value propositions and global value dossiers to communicate product value and facilitate market access. Additionally, Persefoni has significant experience in HTA submissions, early drug pipeline assessments, advisory boards, and systematic/pragmatic literature reviews. Persefoni has worked in a range of disease areas, including musculoskeletal diseases, gastrointestinal disorders, mental disorders, epilepsy, diabetes, and oncology. Persefoni holds a PhD in Duchenne muscular dystrophy from Newcastle University.
Gabriel Jones
Gabriel Jones
Involved in a range of projects, Gabriel has extensive experience of carrying out systematic and pragmatic literature reviews to support submissions to multiple European HTA agencies. As a market access researcher, he has also contributed to reviews to support the value proposition of technologies in global markets and help clients understand the value of their portfolio of products. Gabriel has worked on global value dossiers to support market access of technologies in Europe, North America, and emerging markets, as well as HTA reviews to understand evidence requirements for approval and reimbursement of combination therapies and highly specialised treatments. Gabriel helped to develop PHMR's Market Access Alert service and has been published in high-impact journals. He has also presented work at international conferences in the areas of oncology, endocrinology, and infectious disease.
Craig Keenan
Craig is a statistician with expertise in the delivery of analyses that meet the statistical requirements of key health technology appraisal bodies, including NICE. He conducts a wide range of statistical analyses to support market access and health economics and outcomes research, such as advanced indirect treatment comparison and survival extrapolation methodologies. Craig has worked with a broad range of statistical methods and is proficient with multiple statistical programming languages.
Laura Klein
Laura copyedits and proofreads PHMR’s written materials to the standards required by clients, peer-reviewed journals, and professional organisations. She has extensive experience in publishing and market access consultancies, preparing journal articles for publication and presentations for international conferences. Laura is certified by the Board of Editors in the Life Sciences.
Ewan Laws
As a health economist, Ewan has been involved in the development of cost-effectiveness and budget impact models as well as survival modelling and data extrapolation. Ewan has experience with PRO studies and vignette utility generation, as well as with conducting systematic and targeted literature reviews alongside quantitative data analysis. Ewan's therapeutic areas of expertise include non-alcoholic steatohepatitis, immuno-oncologic agents, Hunter syndrome, and Fabry disease.
Thomas Leahy
Thomas is a statistician and supports market access through real-world evidence studies and indirect treatment comparisons. In particular, he has conducted several Bayesian network-meta analyses and matching-adjusted indirect comparisons in areas including cardiovascular disease, oncology, and neurology. In addition, he has published in peer-reviewed journals on the development of methodologies and in support of market access and post-market access activities. Thomas has been involved in the development of real-world evidence strategies and is proficient in R, Stata, and Python programming languages.
Andrew Lenny
Andrew is a health economist who has been involved in the development, implementation, and evaluation of health outcome measures and valuation surveys. He has advised clients on strategies for the generation of health-related utility data in rare disease areas to support their HTA submissions. In addition, Andrew has expertise in the methodologies used in the valuation of child health and has presented research in this area at international health economics and health outcomes conferences. His research experience spans a range of indications including oncology and lysosomal storage disorders. Andrew holds an MSc in health economics from the University of York.
Helen Lawrence
Helen Lilley
Helen leads the development of value propositions and global value dossiers. She has worked across a wide range of therapeutic areas, including oncology, chronic kidney disease, metabolic disorders, and bladder/bowel health. She is also experienced in conducting systematic literature reviews to support HTA submission and preparing HTA submission dossiers. Helen applies her expert medical writing skills to a broad range of projects at PHMR, including published manuscripts, posters and slide decks.
Ping-Ru Lo
Ping-Ru Lo
Ping has been with PHMR since its foundation helping it develop into a successful health economics, pricing and market access consultancy. Coming from a background in clinical pharmacy both in Germany and the UK, she has changed direction in order to lead the contracting and finance team and set up the internal project management structure.
Aurelie Meunier
Aurelie Meunier
Aurélie is a health economist with broad experience in economic evaluation who has contributed to a variety of projects to support clients' needs from development of health economic models for HTA submissions to payer tools for engagement with national and local payers. Her expertise also stretches to mapping studies and value frameworks in the cell, gene, and rare disease spaces. Aurélie has broad knowledge of HTA methods and of a variety of statistical software packages.
Rachael Miller
Rachael Miller
Rachael has been involved with a range of projects at PHMR and has experience conducting multiple stages of systematic reviews and working with meta-analyses. Previous experience in clinical trial management has also allowed her to develop skills in stringent data analysis, leadership and communication with commercial and academic sponsors, as well as clinical trial patients.
Anne-Sophie Moutié
Anne-Sophie has a wide-ranging experience of health economics and HTA in a range of settings including consultancies, hospitals, pharmaceutical companies and governmental bodies. Such wide-ranging experience has provided her with an in-depth understanding of HTA and reimbursement of pharmaceuticals. Anne-Sophie has developed many HTA submissions for the French HAS (Haute Autorité de Santé) for a range of new therapies including for oncology and orphan designation treatments on behalf of leading pharmaceutical companies. Prior to joining PHMR, Anne-Sophie worked at the Health Products Economics Committee (CEPS) of the French Ministry of Health where she developed valuable insight and experience in pricing processes and negotiations, and evaluation of economic dossiers.
Ayesha Naz
As a market access strategy analyst, Ayesha helps map reimbursement pathways throughout Europe and Asia for rare and orphan disease products, medical technology, and diagnostics. In addition, she has evaluated treatment landscapes, contributed to pricing research and strategy development, organised advisory boards, and produced value messaging across a range of therapeutic areas, including Alzheimer’s disease, nuclear medicine, COVID-19, and uveal melanoma. Before joining PHMR, Ayesha provided clinical services to NHS hospitals. Ayesha holds an MSc in health economics and health policy from the University of Birmingham.
Rachel Payne
Rachel Payne
Rachel is involved in the development of innovative, strategy-based value communications to support market access. She has a particular interest in the use of creative design and digital media to optimise the usability and impact of value communication materials. Rachel has experience in global value dossier development, treatment landscape analysis, reimbursement pathway mapping, literature reviews, peer-reviewed manuscript development, and stakeholder engagement through advisory boards and interviews. She has knowledge in multiple therapeutic areas, including inflammatory bowel disease, antineutrophil cytoplasmic autoantibody–associated vasculitis, cystic fibrosis, and renal disease, and a research and publishing background in nutrition and nutraceuticals. Rachel has a PhD in biological psychology from Northumbria University.
John Petrie
John is a market access researcher with experience in conducting literature reviews, including data extraction and interpretation, as well as communication of complex information in scientific reports. John has contributed to reviews focusing on the economic impact of interventions, as well as the burden of disease on patients and their caregivers, that informed HTA submissions and market access strategy development. John has also published his research in several peer-reviewed journals and presented his work at international conferences in a range of therapeutic areas, including oncology, diabetes, and monoclonal antibody production. He holds a PhD in cellular and molecular biology from Newcastle University.
Ally Robert
Ally is involved in a variety of projects at PHMR to help clients achieve optimal pricing and reimbursement. She has substantial experience in targeted and systematic literature reviews, research and data interpretation, and communicating complex information in slide decks and scientific reports. Ally has delivered multiple project types including reviews of clinical efficacy, burden of illness and HTA processes, mapping of pricing and reimbursement pathways, treatment landscape analysis, stakeholder interviews, strategic recommendations, value message development, and global value dossiers. She has disease area experience in oncology, infectious disease, chronic kidney disease, chronic inflammatory and autoimmune conditions, muscle wasting, and rare diseases. Ally holds a PhD in cellular biology and tissue engineering from Durham University.
Philip Ruane
Philip conducts systematic literature reviews, including data extraction, interpretation, and the communication of results to support HTA submission and for external publication. He also contributes to reviews focusing on the clinical effectiveness of interventions and the burden of chronic conditions on patients and their caregivers. Philip has knowledge in a number of therapeutic areas, including oncology, antineutrophil cytoplasmic autoantibody–associated vasculitis, and cystic fibrosis.
Lucy Sam
Lucy is a market access researcher who has participated in conducting systematic and HTA literature reviews, including screening, data extraction, and quality assessment. She has considerable experience in quantitative and qualitative research. Lucy holds a PhD in public health nutrition from the University of Aberdeen.
Caroline Shaw
Caroline Shaw
Caroline manages and delivers systematic and pragmatic literature reviews. She has conducted reviews of clinical efficacy, economic evaluations, health-related quality of life, and burden of illness, as well as HTA and product labelling reviews, to support market access and reimbursement strategies. Caroline has also undertaken primary market research with payers and key opinion leaders to assess market access opportunities, identify reimbursement pathways, and provide strategic recommendations. She has experience in multiple therapeutic areas, including inflammatory bowel disease, chronic kidney disease, oncology, and neurodegenerative disease. Caroline holds a PhD in nutrition from Newcastle University.
Alexandra Soare
Alexandra is a health economics and outcomes researcher with experience in health state valuation, utility measurement, and mapping studies. She has provided clients with advice on strategies for collecting and analysing patient-reported outcomes data in disease areas characterised by fluctuating health-related quality of life. She has also applied her expertise in mapping approaches to support clients’ needs for obtaining utility data required for their HTA submissions. In addition, Alexandra has led work to assess partitioned survival models and Markov models in the context of advanced non-small cell lung cancer. She has an MSc in health economics and decision modelling from the University of Sheffield.
Elaine Stamp
Elaine Stamp
Elaine is a medical statistician with extensive experience of statistical input into clinical trials and large public health projects, including development of protocols and statistical analysis plans as well as complex data analysis. At PHMR, Elaine's focus has been real-world evidence synthesis and indirect treatment comparisons, working to deliver statistical evidence used to support HTA submissions and inform client decisions. Elaine is experienced in managing large data sets including patient-level health records and hospital episode statistics and has used these to inform clients on burden of disease and prescribing behaviours. Elaine has published in several peer-reviewed journals and is proficient in the use of advanced statistical software, including R, Stata, and WinBUGS. Elaine holds an MMathStat from Newcastle University.
Craig Tallentire
Craig has extensive experience in conducting systematic and pragmatic literature reviews of clinical and economic evidence with quantitative data analyses to inform HTA submissions and other market access and reimbursement activities. Craig has also been involved in the development of value stories and global value dossiers, helping our clients build value for their products. He has experience in several disease areas including oncology, epilepsy, hyperkalaemia, and genetic disorders, and has published peer-reviewed research on neuroendocrine tumours. Craig holds a PhD in the broad area of food sustainability from Newcastle University.
Jasmine Toomey
As a market access research scientist, Jasmine contributes to systematic and targeted literature reviews, including screening and data extraction, as well as HTA reviews to inform market access strategy. She has extensive experience in qualitative and quantitative research. Jasmine is also involved in PHMR’s monthly Market Access Alert service, which helps clients keep up to date with HTA decisions. She holds a PhD in cellular and molecular oncology from Northumbria University, Newcastle.
Dimitris Tzelis

Dimitris is a health economist with broad experience in economic evaluations of therapeutic and diagnostic interventions. He has led and contributed to the conceptualisation and development of cost-effectiveness and budget impact models using a wide range of software. Dimitris has completed a number of projects for a diverse range of funders and clients, including research foundations, pharmaceutical companies, and medical device companies. Dimitris has also conducted systematic literature reviews and diagnostic meta-analyses, and he has broad knowledge of HTA methods and processes. His work covers a wide range of disease areas, including oncology, mental health, metabolic diseases, and rare diseases.

Sophie Walker
As a market access researcher, Sophie contributes to systematic and targeted literature reviews to inform HTA activities. She has experience in communicating complex information in impactful slide decks and concise global value dossiers. Sophie has worked on treatment landscape analyses, mapping of HTA and reimbursement pathways for rare diseases, and recommendations for capturing patient-reported data based on global HTA strategies. Sophie’s interest in market access has led her to coordinate the PHMR monthly Market Access Alert service. She also works with clients to publish peer-reviewed research and develop posters that have been presented at international conferences. Her knowledge of therapeutic areas includes oncology, age-related disease, early development, chronic kidney disease, and rare diseases. Sophie holds an MRes in ageing and health from Newcastle University.
Catherine Watson
Catherine has contributed to a wide range of clinical and economic literature reviews, adopting both pragmatic and systematic approaches. She has supported projects across several therapeutic areas, including oncology, epilepsy, and inflammatory bowel disease, applying extensive prior experience from a clinical trial background. Catherine has assisted in the publication of peer-reviewed research on neuroendocrine tumours and holds a PhD in neuroscience from Newcastle University.
Michael White
Michael has experience in developing communications to demonstrate product value such as evidence-based dossiers. He also has experience in conducting systematic and targeted literature reviews, including data interpretation and synthesis as well as communicating evidence in the form of slide decks, scientific reports, and peer-reviewed manuscripts. Michael has delivered on a range of projects, including reviews of clinical efficacy and burden of illness to support HTA submission and strategic recommendation development. He has knowledge in several disease areas, including oncology, chronic kidney disease, anca-associated vasculitis, diabetes, and cystic fibrosis. Michael has PhD in cellular and molecular biology from Newcastle University.
Ed Wilson
Ed is a health economist with extensive experience in health technology assessment and decision analytic modelling across many therapeutic areas. He has worked at the Universities of York, Cambridge, and East Anglia and published more than 100 peer-reviewed journal articles and book chapters. In addition, Ed has served as a technology appraisal committee member for NICE. He is particularly interested in the value of information analysis (a statistical technique to estimate the return on investment in future research) and expert elicitation (a method to investigate experts’ opinions about plausible values for model parameters in the absence of data). Ed is a member of ConVOI, an international network of experts committed to developing and increasing uptake of value of information methods.
Tibi
Tibi has a part-time role at PHMR. She has expertise in methods for improving health and wellbeing outcomes in workplace settings. Outside of PHMR, Tibi can usually be found networking at nearby Hampstead Heath.
Market access alerts
Our market access alerts are hand-picked items of breaking pricing, reimbursement and market access news.

Alerts